Journal of Hepatology, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 1, 2024
Language: Английский
Cell Metabolism, Journal Year: 2024, Volume and Issue: 36(5), P. 912 - 926
Published: April 11, 2024
Language: Английский
Citations
39
Nature Reviews Disease Primers, Journal Year: 2025, Volume and Issue: 11(1)
Published: March 6, 2025
Language: Английский
Citations
12
Heliyon, Journal Year: 2024, Volume and Issue: 10(9), P. e30387 - e30387
Published: April 25, 2024
Non-alcoholic fatty liver disease (NAFLD) has become one of the most frequent chronic diseases worldwide in recent decades. Metabolic like excessive blood glucose, central obesity, dyslipidemia, hypertension, and function abnormalities cause NAFLD. NAFLD significantly increases likelihood cancer, heart disease, mortality, making it a leading transplants. steatohepatitis (NASH) is more advanced form that causes scarring inflammation over time can ultimately result cirrhosis hepatocellular carcinoma. In this review, we briefly discuss NAFLD's pathogenic mechanisms, their progression into NASH afterward to NASH-related cirrhosis. It also covers epidemiology, metabolic glucose lipid metabolism liver, macrophage dysfunction, bile acid toxicity, stellate cell stimulation. Additionally, consider contribution intestinal microbiota, genetics, epigenetics, ecological factors fibrosis carcinoma risk patients.
Language: Английский
Citations
16
Journal of Hepatology, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 1, 2025
Via regulation of glycemic control and inflammation, free fatty receptor (FFAR)1 4 are potential targets for the treatment MASH. This study tested efficacy safety icosabutate, a FFAR1/FFAR4 agonist, in MASH patients. We performed phase 2b, multicenter, 52-week, randomised, placebo-controlled trial (ICONA) testing icosabutate patients with F1-F3 (mild to severe) fibrosis. Patients were randomized 1:1:1 receive once-daily, oral 300 mg, 600 mg or placebo 52 weeks. The primary endpoint was proportion resolution no worsening fibrosis arm. population analysis comprised 187 [placebo (n=62), (n= 58) (n=67)]. percentage favoured arm without reaching statistical significance (23.9% vs. 14.5%; odds ratio, 2.01; 95% confidence interval [CI], 0.8 5.08; P=0.13). A higher treated achieved ≥1-stage improvement fibrosis, response rate 29.3% (odds 2.89; CI, 1.09 7.70))and 23.9% 2.4; 0.90 6.37)) 11.3% An observed using AI-assisted digital pathology. Marked decreases biomarkers liver damage observed. Icosabutate generally safe well tolerated, mild moderate TEAEs reports drug induced injury. Although not met, demonstrated encouraging (as measured by both conventional pathology) non-invasive biomarker data, supporting further development NCT04052516 IMPACT AND IMPLICATIONS: • With expression on multiple cells types regulating targeting acid receptors 1 could offer an attractive approach fibrosing it's comorbidities.• (a agonist) did meet pre-defined (MASH fibrosis), overall dataset (including suggest patients.• Improvements damage, inflammation therapy.• well-tolerated, data support patients, particular those more advanced disease (F2-F3 fibrosis) type 2 diabetes.
Language: Английский
Citations
2
Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 722 - 722
Published: Feb. 20, 2025
Metabolic dysfunction-associated steatotic liver disease (MASLD) is emerging as a leading cause of chronic disease. In recent years, artificial intelligence (AI) has attracted significant attention in healthcare, particularly diagnostics, patient management, and drug development, demonstrating immense potential for application implementation. the field MASLD, substantial research explored AI various areas, including counseling, improved stratification, enhanced diagnostic accuracy, prognosis prediction. However, integration hepatology not without challenges. Key issues include data management privacy, algorithmic bias, risk AI-generated inaccuracies, commonly referred to "hallucinations". This review aims provide comprehensive overview applications hepatology, with focus on highlighting both its transformative inherent limitations.
Language: Английский
Citations
2
Journal of Hepatology, Journal Year: 2023, Volume and Issue: 80(6), P. e279 - e281
Published: Nov. 28, 2023
Language: Английский
Citations
21
Materials Today Bio, Journal Year: 2024, Volume and Issue: 26, P. 101028 - 101028
Published: March 24, 2024
The expansion applications of semiconducting polymer dots (Pdots) among optical nanomaterial field have long posed a challenge for researchers, promoting their intelligent application in multifunctional nano-imaging systems and integrated nanomedicine carriers diagnosis treatment. Despite notable progress, several inadequacies still persist the Pdots, including development simplified near-infrared (NIR) nanoprobes, elucidation inherent biological behavior, integration information processing nanotechnology into biomedical applications. This review aims to comprehensively elucidate current status Pdots as classical nanophotonic material by discussing its advantages limitations terms biocompatibility, adaptability microenvironments vivo, etc. Multifunctional surface chemistry play crucial roles realizing Pdots. Information visualization based on physicochemical properties is pivotal achieving detection, sensing, labeling probes. Therefore, we refined underlying mechanisms constructed multiple comprehensive original mechanism summaries establish benchmark. Additionally, explored cross-linking interactions between nanomedicine, potential yet complete metabolic pathways, future research directions, innovative solutions integrating treatment strategies. presents possible expectations valuable insights advancing specifically from chemical, medical, photophysical practitioners' standpoints.
Language: Английский
Citations
8
Hepatology, Journal Year: 2024, Volume and Issue: unknown
Published: June 25, 2024
Background and Aims: Antifibrotic trials rely on conventional pathology despite recognized limitations. We compared single-fiber digital image analysis with to quantify the antifibrotic effect of Aramchol, a stearoyl-CoA desaturase 1 inhibitor in development for metabolic dysfunction–associated steatohepatitis. Approach Results: Fifty-one patients steatohepatitis enrolled open-label part ARMOR trial received Aramchol 300 mg BID had paired pre-post treatment liver biopsies scored by consensus among 3 hepatopathologists, separately assessed platform (PharmaNest) that generates continuous phenotypic Fibrosis Composite Severity (Ph-FCS) score. improvement was defined as: ≥1 NASH Clinical Research Network (NASH-CRN) stage reduction; “improved” ranked pair assessment; reduction Ph-FCS (“any” ≥0.3 absolute “substantial” ≥25% relative reduction). improved 31% (NASH-CRN), 51% (ranked assessment), 74.5% (any reduction), 41% (substantial Most stable fibrosis NASH-CRN or assessment (a third substantial increased duration: 25% <48 weeks versus 39% ≥48 NASH-CRN; 43% 61% assessment, mean −0.54 (SD: 1.22) −1.72 1.02); 54% vs. 100%, 21% 65%). The corroborated reductions stiffness, Pro-C3, enhanced fibrosis. Changes were positively correlated changes stiffness. Conclusions: Continuous scores generated effects greater sensitivity larger dynamic range than pathology.
Language: Английский
Citations
7
Hepatology Communications, Journal Year: 2025, Volume and Issue: 9(1)
Published: Jan. 1, 2025
Histopathologic evaluation of liver biopsy has played a longstanding role in the diagnosis and management disease. However, utility been questioned by some, given improved imaging modalities, increased availability noninvasive serologic tests, development artificial intelligence over past several years. In this review, we discuss current future both non-neoplastic neoplastic diseases era laboratory, radiologic, digital technologies.
Language: Английский
Citations
1
JHEP Reports, Journal Year: 2025, Volume and Issue: unknown, P. 101421 - 101421
Published: April 1, 2025
Language: Английский
Citations
1